Testoluten®
In addition to conventional therapy, patients in the primary group (22 people) received TESTOLUTEN®
1 capsule 2 times a day with meals for 30 days.
Distribution of patients by groups. Table 1
Diagnosis Control Group Primary Group
Age Number of Age Number of
Patients Patients
Male Climax 47-64 14 49-65 22
RESEARCH METHODS
Patients’ complaints were assessed in dynamics, and general clinical examination of blood and urine,
biochemical blood study using the REFLOTRON apparatus (Boehringer Mannheim, Germany) were
carried out. Using a radioimmunological method, the content of sex hormones in the blood serum
was determined. The radioactivity of the samples was counted on the «Tracor Analytic 1285» counter
(USA-Holland). In addition, palpation of the prostate gland, laboratory examinations of secretion and
ejaculation were performed.
RESEARCH RESULTS
The studies showed that in the examined patients, the manifestations of male climax result from
predominantly hormonal changes in the body, characteristic of this age group. The severity of these
manifestations in younger people is also due to various unfavorable environmental and occupational
factors. An increase in blood glucose was noted in some patients, which probably indicates a “break-
down” of the insulin regulation system.
Changes in the concentration of sex hormones in the blood were characteristic (Table 2).
In almost all patients, genetic changes in the prostate gland were determined by palpation.
The use of TESTOLUTEN® against the background of complex treatment helped improve the general
well-being of patients and increase libido.
It is imperative to note that TESTOLUTEN® had a regulatory effect on the content of sex hormones
in the blood (Table 2). As can be seen from the data in Table 2, before treatment, the ratio of sex hor-
mones was disrupted in all patients, while the content of all hormones, including testosterone, was at
the lower limit of the norm. The use of TESTOLUTEN® led to a significant increase in the content of
luteinizing hormone (LH) and follicle-stimulating hormone (FSH) compared with the indicators both
before treatment and in patients in the control group who received conventional therapy without
hormonal drugs.
It is important to note that as a result of the use of TESTOLUTEN®, the testosterone content in the
blood of patients of the primary group significantly increased compared to the indicator before treat-
ment. No significant increase in testosterone content was observed in the patient’s blood in the con-
trol group.
Для таблиц, дозировок и примечаний сверяйтесь с оригинальным PDF: при извлечении текста порядок колонок может измениться.
Из библиотеки Peptides. Авторство и содержание оригинала сохранены. Размещено с разрешения поставщика.